Compare Genuine Parts Company (GPC) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Moderna, Inc. — how do they compare? Genuine Parts Company trades at $127.56 (market cap $17.67B), while Moderna, Inc. trades at $198 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 4.5× Genuine Parts Company's market cap, and Genuine Parts Company pays a 3.32% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Moderna, Inc. for 59 Days on average.
| GPC | MRNA | |
|---|---|---|
Market Cap | $17.67B | $78.65B |
Volume | 1,079,458 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $203.46 |
52-Week Low | $92.47 | $22.36 |
Typical Hold Time | 75 Days | 59 Days |
Enterprise Value | $23.76B | $74.80B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $125.41, down 1.55% today, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, with Q3 2026 results due October 20, 2026. Revenue grew to $24.3B in 2025, but net income margin fell sharply to 0.13%. Analyst consensus is a $145.75 price target with 43% buy ratings. Key developments include the planned spinoff of its industrial unit, Motion, in Q1 2027.
The outlook is cautious due to weak profitability and high P/E, but the spinoff could unlock value. Risks include execution challenges and economic sensitivity. Upside hinges on margin recovery and successful separation.
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
